Logo
Phone Icon
1-855-4-MEDINFO (855-463-3463)

1-855-4-MEDINFO (855-463-3463)

[email protected]
Back

INCB161734

INCB161734 is an investigational, oral, selective inhibitor of G12D-mutated KRAS.1

Recruiting & Ongoing Clinical Studies

Condition
Study Title
Phase
Resources & Links
Pancreatic ductal adenocarcinoma
DAWN-303: A Randomized, Double-Blind Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
3
NCT07522073 View Resource
Solid tumors
An Open-Label Study of INCB161734 Monotherapy or in Combination With Retifanlimab-dlwr, Cetuximab ± Chemotherapy, GEMNabP, mFOLFIRINOX, or INCA33890 in Patients With Advanced or Metastatic Solid Tumors With KRASG12D Mutation
1
NCT06179160 View Resource

G12D-Mutated Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

G12D-Mutated Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

KRAS proteins function as molecular switches, controlling multiple signaling cascades that promote survival and proliferation.2,3

KRAS is one of the most frequently altered driver oncogenes in solid tumors.4,5

G12D is the most common KRAS mutant isoform (comprising ≈29% of oncogenic mutations in KRAS), with a high incidence in pancreatic and colorectal cancers and non-squamous NSCLC.4,a

aData from 426,706 unique tissue or hematologic samples submitted for testing during routine clinical care from December 2013 to December 2021.4

References: 1. Farren MR, et al. AACR 2024. Poster 5900. 2. Erlanson DA, Webster KR. Curr Opin Chem Biol. 2021;62:101-108. 3. Simanshu DK, et al. Cell. 2017;170:17-33. 4. Lee JK, et al. NPJ Precis Oncol. 2022;6:91. 5. Zehir A, et al. Nat Med. 2017;23:703-713.

Top